Aeglea Bio Therapeutics Inc AGLE:NASDAQ

Last Price$6.09Cboe Real-Time Last Sale as of 12:41PM ET 12/01/21
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.15(2.40%)
Bid (Size)$6.09 (200)
Ask (Size)$6.15 (6)
Day Low / High$6.05 - 6.37
Volume36.5 K

View Biotechnology IndustryPeer Comparison as of 12/01/2021


Aeglea Bio Therapeutics Inc ( NASDAQ )

Price: $6.09
Change: -0.15 (2.40%)
Volume: 36.5 K
12:41PM ET 12/01/2021

Evolus Inc ( NASDAQ )

Price: $5.74
Change: +0.20 (3.61%)
Volume: 222.8 K
12:48PM ET 12/01/2021

Verrica Pharmaceuticals Inc ( NASDAQ )

Price: $9.60
Change: -0.75 (7.25%)
Volume: 19.3 K
12:47PM ET 12/01/2021

PDS Biotechnology Corp ( NASDAQ )

Price: $9.58
Change: -0.27 (2.74%)
Volume: 124.9 K
12:39PM ET 12/01/2021

Checkpoint Therapeutics Inc ( NASDAQ )

Price: $3.02
Change: +0.06 (2.03%)
Volume: 308.9 K
12:36PM ET 12/01/2021

Read more news Recent News

-- Earnings Flash (AGLE) AEGLEA BIOTHERAPEUTICS Posts Q3 Revenue $1.4M
7:01AM ET 11/04/2021 MT Newswires


Insider Trends: 90-Day Insider Selling Trend at Aeglea BioTherapeutics Slowed with Acquisition of Shares
5:24PM ET 8/18/2021 MT Newswires

Jonathan Alspaugh, CFO, executed a purchase for 40,372 shares of Aeglea BioTherapeutics (AGLE) on Aug 16, 2021, for $262,660. Alspaugh, after the...

-- Earnings Flash (AGLE) AEGLEA BIOTHERAPEUTICS Posts Q2 Revenue $13.7M
8:31AM ET 8/05/2021 MT Newswires


Aeglea BioTherapeutics' Pegzilarginase Cited as Potential Treatment for Arginase 1 Deficiency in Inherited Metabolic Disorders Journal
5:00PM ET 7/14/2021 MT Newswires

Aeglea BioTherapeutics (AGLE) said Wednesday its pegzilarginase was published in the Journal of Inherited Metabolic Disease as a potential treatment for...

View all Commentary and Analysis

Tracking Baker Brothers Portfolio - Q2 2021 Update
12:54AM ET 10/05/2021 Seeking Alpha

Aeglea BioTherapeutics (AGLE) Investor Presentation - Slideshow
2:05PM ET 9/10/2021 Seeking Alpha

Acer Therapeutics: Deriving Value By Developing Therapies For Rare Diseases
6:43PM ET 8/31/2021 Seeking Alpha

Tracking Baker Brothers Portfolio - Q1 2021 Update
7:50AM ET 7/08/2021 Seeking Alpha

Company Profile

Business DescriptionAeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which develops next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX. View company web site for more details
Address805 Las Cimas Parkway
Austin, Texas 78746
Number of Employees61
Recent SEC Filing11/16/20214
President, Chief Executive Officer & DirectorAnthony G. Quinn
Chief Operating OfficerLeslie Sloan
Chief Financial OfficerJonathan D. Alspaugh
Chief Accounting Officer, VP & ControllerSteven Weber

Company Highlights

Price Open$6.37
Previous Close$6.24
52 Week Range$5.82 - 9.78
Market Capitalization$300.4 M
Shares Outstanding49.3 M
SectorHealth Technology
Next Earnings Announcement03/17/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.16
Beta vs. S&P 500N/A
Revenue$3.9 M
Net Profit Margin-450.94%
Return on Equity-56.18%

Analyst Ratings as of 03/24/2021

Consensus RecommendationConsensus Icon
Powered by Factset